RESUMEN

A new HPLC procedure with precolumn derivatization and rimantadine as the internal standard for determining memantine, a candidate agent for the treatment of glaucoma in plasma and vitreous humour, has been developed and validated. Precolumn derivatization was performed with 9-fluorenylmethyl-chloroformate-chloride (FMOC-Cl) as the derivatization reagent and followed by a liquid-liquid extraction with n-hexane. Optimal conditions for derivatization were an FMOC-Cl concentration of 1.5 mM, a reaction time of 20 min, the temperature at 30°C, the borate buffer pH 8.5, and a borate buffer-acetonitrile ratio of 1:1. The derivatives were analyzed by isocratic HPLC with the fluorescence detector λex 260 nm λem 315 nm on a Novapack C(18) reversed-phase column with a mobile phase of acetonitrile-water (73:27, v/v), 40°C, and a flow rate of 1.2 mL/min. The linear range was 10-1000 ng/mL with a quantification limit of ∼ 10 ng/mL for both types of samples. This analytical method may be suitable for using in ocular availability studies.

Asunto(s)

Cromatografía Líquida de Alta Presión/métodos , Memantina/análisis , Espectrometría de Fluorescencia/métodos , Cuerpo Vítreo/química , Animales , Estabilidad de Medicamentos , Fluorenos/química , Hexanos/química , Concentración de Iones de Hidrógeno , Modelos Lineales , Memantina/sangre , Memantina/química , Memantina/farmacocinética , Conejos , Reproducibilidad de los Resultados , Rimantadina/análisis , Rimantadina/sangre , Sensibilidad y Especificidad